SCYNEXIS (SCYNEXIS) Total Stockholders Equity : $74.1 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is SCYNEXIS Total Stockholders Equity?

SCYNEXIS's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $74.1 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. SCYNEXIS's Book Value per Share for the quarter that ended in Mar. 2024 was $1.96. The ratio of a company's debt over equity can be used to measure how leveraged this company is. SCYNEXIS's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.04.

SCYNEXIS Total Stockholders Equity Historical Data

The historical data trend for SCYNEXIS's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Total Stockholders Equity Chart

SCYNEXIS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

12.90

22.76

41.26

3.23

72.96

SCYNEXIS Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															-29.91	93.08	91.99	72.96	74.11

SCYNEXIS (NAS:SCYX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

SCYNEXIS's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(74.105	-	0)	/	37.7798
	=	1.96

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

SCYNEXIS's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.356	+	2.487)	/	74.105
	=	0.04

SCYNEXIS Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS (SCYNEXIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (NAS:SCYX) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

135A:Germany 135A:Germany

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

Executives

David C Hastings	director	C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Brian Philippe Tinmouth	director	1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Guy Macdonald	director	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Ann Hanham	director	ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Armando Anido	director	80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Ivor Macleod	officer: Chief Financial Officer	3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
Scott Sukenick	officer: General Counsel	101 HUDSON STREET, SUITE 3610, JERSEY CITY NJ 07302
Marco Taglietti	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Lawrence R Hoffman	officer: Interim CFO	C/O COVALENT GROUP, INC., 1275 DRUMMERS LANE, SUITE 100, WAYNE PA 19087
Christine Coyne	officer: Chief Commercial Officer	1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric Francois	officer: Chief Financial Officer	C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Gonzalez David Angulo	officer: Chief Medical Officer	C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713